
Benjamin P. Blumel
Examiner (ID: 13928, Phone: (571)272-4960 , Office: P/1648 )
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1648, 1671 |
| Total Applications | 1338 |
| Issued Applications | 802 |
| Pending Applications | 145 |
| Abandoned Applications | 411 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16511623
[patent_doc_number] => 20200390880
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => Filovirus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using Same
[patent_app_type] => utility
[patent_app_number] => 17/004818
[patent_app_country] => US
[patent_app_date] => 2020-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25695
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 324
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17004818
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/004818 | Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same | Aug 26, 2020 | Issued |
Array
(
[id] => 17665533
[patent_doc_number] => 11359214
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-14
[patent_title] => Simian (gorilla) adenovirus or adenoviral vectors and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/002064
[patent_app_country] => US
[patent_app_date] => 2020-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13783
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17002064
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/002064 | Simian (gorilla) adenovirus or adenoviral vectors and methods of use | Aug 24, 2020 | Issued |
Array
(
[id] => 16506433
[patent_doc_number] => 20200385689
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-10
[patent_title] => SCALABLE PRODUCTION METHOD FOR AAV
[patent_app_type] => utility
[patent_app_number] => 16/998548
[patent_app_country] => US
[patent_app_date] => 2020-08-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7834
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16998548
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/998548 | Scalable production method for AAV | Aug 19, 2020 | Issued |
Array
(
[id] => 16756602
[patent_doc_number] => 10975139
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-04-13
[patent_title] => Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments
[patent_app_type] => utility
[patent_app_number] => 16/996297
[patent_app_country] => US
[patent_app_date] => 2020-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 17
[patent_no_of_words] => 45397
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996297
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/996297 | Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments | Aug 17, 2020 | Issued |
Array
(
[id] => 18281618
[patent_doc_number] => 20230097090
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS
[patent_app_type] => utility
[patent_app_number] => 17/634516
[patent_app_country] => US
[patent_app_date] => 2020-08-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 65190
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -63
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634516
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/634516 | IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | Aug 13, 2020 | Pending |
Array
(
[id] => 17400895
[patent_doc_number] => 20220042985
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => SARS-CoV-2 IgG/IgM ANTI-BODY DETECTION KIT
[patent_app_type] => utility
[patent_app_number] => 16/987049
[patent_app_country] => US
[patent_app_date] => 2020-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5047
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16987049
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/987049 | SARS-CoV-2 IgG/IgM ANTI-BODY DETECTION KIT | Aug 5, 2020 | Abandoned |
Array
(
[id] => 18116384
[patent_doc_number] => 11547756
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-10
[patent_title] => Method of treating influenza A
[patent_app_type] => utility
[patent_app_number] => 16/984827
[patent_app_country] => US
[patent_app_date] => 2020-08-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 23376
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16984827
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/984827 | Method of treating influenza A | Aug 3, 2020 | Issued |
Array
(
[id] => 17805915
[patent_doc_number] => 20220257750
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => PROTEOLYSIS-TARGETING VIRUS, LIVE VACCINE THEREOF, PREPARATION METHOD AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/624822
[patent_app_country] => US
[patent_app_date] => 2020-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12604
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17624822
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/624822 | PROTEOLYSIS-TARGETING VIRUS, LIVE VACCINE THEREOF, PREPARATION METHOD AND USE THEREOF | Jul 2, 2020 | Pending |
Array
(
[id] => 16336556
[patent_doc_number] => 10787501
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2020-09-29
[patent_title] => Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
[patent_app_type] => utility
[patent_app_number] => 16/912678
[patent_app_country] => US
[patent_app_date] => 2020-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 17
[patent_no_of_words] => 45364
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16912678
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/912678 | Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments | Jun 24, 2020 | Issued |
Array
(
[id] => 16948411
[patent_doc_number] => 20210207102
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => VIRUS-LIKE PARTICLES CO-EXPRESSING TOXOPLASMA GONDII IMC, ROP18, AND MIC8, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/901705
[patent_app_country] => US
[patent_app_date] => 2020-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12590
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16901705
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/901705 | Virus-like particles co-expressing | Jun 14, 2020 | Issued |
Array
(
[id] => 16466807
[patent_doc_number] => 20200368344
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => CHIKV RNA VACCINES
[patent_app_type] => utility
[patent_app_number] => 16/898268
[patent_app_country] => US
[patent_app_date] => 2020-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70414
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16898268
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/898268 | CHIKV RNA vaccines | Jun 9, 2020 | Issued |
Array
(
[id] => 18503630
[patent_doc_number] => 11701420
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-18
[patent_title] => Parenteral norovirus vaccine formulations
[patent_app_type] => utility
[patent_app_number] => 16/894291
[patent_app_country] => US
[patent_app_date] => 2020-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 21
[patent_no_of_words] => 17462
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 127
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16894291
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/894291 | Parenteral norovirus vaccine formulations | Jun 4, 2020 | Issued |
Array
(
[id] => 17134833
[patent_doc_number] => 11136379
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-05
[patent_title] => Binding molecules directed against influenza hemagglutinin and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/946092
[patent_app_country] => US
[patent_app_date] => 2020-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 32
[patent_no_of_words] => 27971
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16946092
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/946092 | Binding molecules directed against influenza hemagglutinin and uses thereof | Jun 4, 2020 | Issued |
Array
(
[id] => 20729114
[patent_doc_number] => 12636358
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-05-26
[patent_title] => Recombinant non-structural protein 1, recombinant influenza virus and immunological composition including the same, and method of treating or preventing disease or condition caused by or associated with influenza virus
[patent_app_type] => utility
[patent_app_number] => 17/616583
[patent_app_country] => US
[patent_app_date] => 2020-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 25
[patent_no_of_words] => 3516
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616583
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/616583 | Recombinant non-structural protein 1, recombinant influenza virus and immunological composition including the same, and method of treating or preventing disease or condition caused by or associated with influenza virus | Jun 3, 2020 | Issued |
Array
(
[id] => 18036195
[patent_doc_number] => 20220380410
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => Live Attenuated Universal Influenza Virus Vaccines, Methods and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/616137
[patent_app_country] => US
[patent_app_date] => 2020-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20116
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616137
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/616137 | Live Attenuated Universal Influenza Virus Vaccines, Methods and Uses Thereof | Jun 1, 2020 | Pending |
Array
(
[id] => 16414503
[patent_doc_number] => 10822379
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2020-11-03
[patent_title] => Molecules that bind to SARS-CoV-2
[patent_app_type] => utility
[patent_app_number] => 15/931939
[patent_app_country] => US
[patent_app_date] => 2020-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 16
[patent_no_of_words] => 35658
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15931939
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/931939 | Molecules that bind to SARS-CoV-2 | May 13, 2020 | Issued |
Array
(
[id] => 17890761
[patent_doc_number] => 11453714
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-27
[patent_title] => Human antibodies to influenza hemagglutinin
[patent_app_type] => utility
[patent_app_number] => 16/870669
[patent_app_country] => US
[patent_app_date] => 2020-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 34477
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 274
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16870669
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/870669 | Human antibodies to influenza hemagglutinin | May 7, 2020 | Issued |
Array
(
[id] => 19389882
[patent_doc_number] => 20240279752
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => PROTECTION SEQUENCE, PRIMER, PROBE, COMPOSITION AND KIT FOR STEADY-STATE RAPID DETECTION OF NOVEL CORONAVIRUS, AND USE THEREOF AND METHOD THEREFOR
[patent_app_type] => utility
[patent_app_number] => 18/004410
[patent_app_country] => US
[patent_app_date] => 2020-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7752
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18004410
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/004410 | PROTECTION SEQUENCE, PRIMER, PROBE, COMPOSITION AND KIT FOR STEADY-STATE RAPID DETECTION OF NOVEL CORONAVIRUS, AND USE THEREOF AND METHOD THEREFOR | May 5, 2020 | Pending |
Array
(
[id] => 16267421
[patent_doc_number] => 20200268908
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => RABIES VACCINE
[patent_app_type] => utility
[patent_app_number] => 16/865107
[patent_app_country] => US
[patent_app_date] => 2020-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31427
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16865107
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/865107 | Rabies vaccine | Apr 30, 2020 | Issued |
Array
(
[id] => 16238631
[patent_doc_number] => 20200255865
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => SINGLE CYCLE REPLICATING ADENOVIRUS VECTORS
[patent_app_type] => utility
[patent_app_number] => 16/863705
[patent_app_country] => US
[patent_app_date] => 2020-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4584
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16863705
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/863705 | Single cycle replicating adenovirus vectors | Apr 29, 2020 | Issued |